

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Provisional Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • MerckSerono (cetuximab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> ▪ Age Concern England ▪ Black Health Agency (BHA) ▪ Cancer Black Care ▪ Cancer Equality ▪ Cancer Voices ▪ Cancerbackup ▪ Chinese National Healthy Living Centre ▪ Confederation of Indian Organisations ▪ Counsel and Care ▪ Equalities National Council ▪ Get A-Head ▪ Help the Aged ▪ Let's Face It ▪ Macmillan Cancer Relief ▪ Maggie's Centres ▪ Marie Curie Cancer Care ▪ Mouth Cancer Foundation ▪ Muslim Council of Great Britain ▪ Muslim Health Network ▪ National Association Of Laryngectomee Clubs ▪ National Cancer Alliance ▪ National Council for Palliative Care ▪ Rarer Cancers Forum 	<p><u>General</u></p> <ul style="list-style-type: none"> ▪ Age Concern Cymru ▪ Board of Community Health Councils in Wales ▪ Cancer Care Cymru ▪ British National Formulary ▪ Department of Health, Social Services and Public Safety for Northern Ireland ▪ Medicines and Healthcare products Regulatory Agency (MHRA) ▪ National Public Health Service for Wales ▪ NHS Confederation ▪ NHS Purchasing and Supply Agency ▪ NHS Quality Improvement Scotland ▪ Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> ▪ Mayne Pharma plc (cisplatin, carboplatin and 5-fluorouracil) ▪ Wockhardt UK Ltd (cisplatin, carboplatin and 5-fluorouracil) ▪ Pharmacia Limited (cisplatin) ▪ Medac UK (5-fluorouracil) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> ▪ Head and Neck Cancer Research Trust ▪ Institute of Cancer Research ▪ King's College Hospital Maxillofacial Unit - The Head and Neck Oncology

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> ▪ Specialised Healthcare Alliance ▪ South Asian Health Foundation ▪ Tenovus Cancer Information Centre <p><u>Professional groups</u></p> <ul style="list-style-type: none"> ▪ Association of Cancer Physicians ▪ Association of Surgeons of Great Britain and Ireland ▪ British Association for Services to the Elderly ▪ British Association of Head and Neck Oncologists ▪ British Association of Head and Neck Oncology Nurses ▪ British Association of Otorhinolaryngologists - Head and Neck Surgeons ▪ British Association of Oral and Maxillofacial Surgeons ▪ British Association of Surgical Oncology ▪ British Geriatric Society ▪ British Oncological Association (BOA) ▪ Cancer Networks Pharmacists Forum ▪ British Psychosocial Oncology Society ▪ Cancer Research UK ▪ Royal College of Anaesthetists ▪ Royal College of General Practitioners ▪ Royal College of Nursing ▪ Royal College of Pathologists ▪ Royal College of Physicians, Medical Oncology Joint Special Committee ▪ Royal College of Radiologists ▪ Royal College of Surgeons ▪ Royal Pharmaceutical Society ▪ Royal Society of Medicine – Intellectual Disabilities Forum ▪ The Society and College of Radiographers ▪ UK Oncology Nursing Society 	<ul style="list-style-type: none"> ▪ MRC Clinical Trials Unit ▪ National Cancer Research Institute ▪ Policy Research Institute on Ageing and Ethnicity <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> ▪ Evidence Review Group tbc ▪ National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> ▪ National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> ▪ (none)

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> ▪ Department of Health ▪ Newport LHB ▪ Tower Hamlets PCT ▪ Welsh Assembly Government 	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Issue date: September 2007

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the topic.

<i>Consultees</i>	
Manufacturer	Generic Name
Merck Pharmaceuticals	cetuximab
<i>Commentators</i>	
Manufacturer	Generic Name
Mayne Pharma plc	cisplatin, carboplatin and 5-fluorouracil
Wockhardt UK Ltd	cisplatin, carboplatin and 5-fluorouracil
Pharmacia Limited	cisplatin

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Issue date: September 2007

Page 5 of 6

Medac UK	5-fluorouracil
----------	----------------

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed appraisal of cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Issue date: September 2007